[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

+32 2 723 26 68

Email address

linda.sano@ppdi.com

Condition

Parkinson Disease,Parkinson's Disease

Treatment type

Interventional

Investigational product

DNL151

Phase

Phase 1

Sponsor

Denali Therapeutics Inc.

ClinicalTrials.gov identifier

NCT04056689

Study number

DNLI-C-0003

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. Body mass index (BMI) between 18 and 35.0 kg/m2, inclusive
  2. Clinical diagnosis of Parkinson's disease meeting UK Brain Bank criteria and H&Y Stage I, II, or III.
  3. Able to hold Parkinson's disease medications 8 hours (overnight) prior to specific study assessments
Exclusion criteria
  1. Any history of clinically significant asthma, chronic obstructive pulmonary disease, or emphysema within 5 years of screening, or other clinically significant pulmonary disease within 6 months of screening
  2. Abnormal Vitals including Respiratory Rate, Body Temperature, Blood Pressure, and Pulse Rate
  3. Pulmonary Function Tests (PFTs) (FVC <60% predicted, FEV1 <50% predicted, FEV1:FVC ratio <0.6, DLCO <70% predicted)
  4. Clinically significant neurologic disorder other than Parkinson's disease, including history of stroke within 12 months of screening, cognitive impairment, seizure within 5 years of screening, or head trauma with loss of consciousness within 6 months of screening
  5. Montreal Cognitive Assessment (MoCA) score of <24 at screening

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site